No statistically significant differences in eye disease/corneal scarring were observed between Pax6-SPP-/- and WT control mice on days 2, 4, 8 and 14 PI (Fig 6A, p>0.05, Fisher’s exact test), while eye disease/corneal scarring was significantly lower in Pax6-SPP-/- mice than WT control mice on days 21 and 28 PI (Fig 6A, p<0.05, Fisher’s exact test). Here, PAX6 is linked to eye disorder.